Biosion, a clinical stage biotech company with operations in Delaware, US, and China, has entered into a licensing agreement with US based Acraris Therapeutics, Inc. (NASDAQ: ACRS). The deal grants Acraris exclusive global rights, excluding Greater China, to Biosion’s BSI-045B and BSI-502, further strengthening the two companies’ layout in the field of immunomodulatory therapy.
Terms of the Deal
Under the terms of the agreement, Biosion will receive an upfront payment and partial development and product materials costs totaling over USD 40 million in cash. Additionally, Biosion is eligible for research and development and sales milestone payments exceeding USD 900 million, as well as single-digit sales commissions. As part of the deal, Biosion will also acquire a 19.9% stake in Aclaris Therapeutics.
About BSI-045B and BSI-502
BSI-045B is a humanized anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody (mAb) that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. This mechanism prevents immune cells targeted by TSLP from releasing proinflammatory cytokines. BSI-045B is currently in clinical development.
BSI-502 is a humanized anti-TSLP and anti-interleukin 4 receptor (IL4R) bispecific antibody that blocks both the upstream TSLP receptor signal transduction and downstream IL4R activation, thereby inhibiting a central proinflammatory pathway. BSI-502 is under pre-clinical development.-Fineline Info & Tech
Leave a Reply